Sandostatin LAR Depot (octreotide acetate for injectable suspension) is a prescription medicine indicated for:
Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.
Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome.
Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.
Treatment of TSH-secreting pituitary adenomas:
when secretion has not normalised after surgery and/or radiotherapy;
in patients in whom surgery is inappropriate;
in irradiated patients, until radiotherapy is effective
This information is based on the Sandostatin LAR European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.